<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154491</url>
  </required_header>
  <id_info>
    <org_study_id>PAHFRAC-01</org_study_id>
    <secondary_id>2009-015865-30</secondary_id>
    <nct_id>NCT01154491</nct_id>
  </id_info>
  <brief_title>Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period</brief_title>
  <acronym>PAHFRAC</acronym>
  <official_title>Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to evaluate the efficacy of ferric carboxymaltose + erythropoietin versus ferric
      carboxymaltose versus placebo in reducing the percentage of patients who receive red-cell
      transfusion in the perioperative period of hip fracture, a multicenter, randomized, parallel
      groups, double-blind clinical trial in adult patients admitted for osteoporotic hip fracture
      is designed. Required sample size is of 87 patients per arm (87x3 = 261). Primary efficacy
      variable is the percentage of patients who receive red-cell transfusion during
      hospitalization; secondary end-points: average red-cell packs per patient,haemoglobin at 24 h
      and 72h after the intervention, at the time of hospital discharge and 60 days after hospital
      discharge, hospital stay and mortality during hospital-stay and 60 days afterwards. Adverse
      clinical events and side effects are assessed as safety variables. In addition health related
      quality of life will be measured at inclusion and after 60 days. A cost-efficacy analysis (by
      means of incremental cost-efficacy method using as a primary endpoint each patient not
      requiring transfusion, and as secondary end-point every patient who survived the index
      admission is performed). The investigators would like to demonstrate a double benefits:
      optimizing precious resource such as blood products and reducing complications arising from
      their use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three arms of treatments: A: ferric carboxymaltose and erythropoietin, B: ferric
      carboxymaltose and placebo, arm C: two placebos. Primary objective:reduction of red-cell
      packs needed for elderly patients with osteoporotic hip fracture which requires surgical
      intervention in the perioperative period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduce red-cell transfusion packs</measure>
    <time_frame>60 days after hospital discharge</time_frame>
    <description>percentage of patients who receive red-cell transfusion during hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average red-cell packs per patient</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>24 h and 72h after the intervention, at the time of hospital discharge and 60 days after hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization days</measure>
    <time_frame>end of study</time_frame>
    <description>number of days inhospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death rate with all causes mortality</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>end of study</time_frame>
    <description>adverse clinical events, side effects, Serious Adverse Events (SAE) and Suspected Unexpected Serious Adverse Reaction(SUSAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>end of study</time_frame>
    <description>health related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-efficacy analysis</measure>
    <time_frame>end of study</time_frame>
    <description>means of incremental cost-efficacy method (using as a primary endpoint each patient not requiring transfusion, and as secondary end-point every patient who survived the index admission)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebos: placebo for ferric carboxymaltose and placebo for erythropoietin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric carboxymaltose and placebo for erythropoietin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPOFE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferric carboxymaltose and erythropoietin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.
Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.</description>
    <arm_group_label>FE</arm_group_label>
    <arm_group_label>EPOFE</arm_group_label>
    <other_name>Intravenous iron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Erythropoetin: 40,000 units subcutaneous (unique dose).</description>
    <arm_group_label>EPOFE</arm_group_label>
    <other_name>EPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.
Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 65 years and older.

          -  Osteoporotic hip fracture which require surgical intervention

          -  Haemoglobin levels between 90-120 g/L

          -  Signed informed consent form

        Exclusion Criteria:

          -  Bone marrow diseases which could interfere in the erythropoietic process (acute or
             chronic myelodysplastic syndromes or myeloproliferative diseases, and/or infiltration
             of the bone marrow due to solid or lymphatic neoplasms)

          -  Blood coagulation diseases or currently treated with oral anticoagulants and/or
             heparin at therapeutic doses.

          -  Documented allergy and/or previous intolerance and/or contraindication of
             erythropoietin use and/or intravenous iron.

          -  Patients with rheumatoid arthritis and/or another demonstrated origin of inflammatory
             anemia and/or not controlled arterial hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Máximo Bernabeu-Wittel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen del Rocio. Sevilla</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vega Baja</name>
      <address>
        <city>Orihuela</city>
        <state>Alicante</state>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <state>España</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipúzcoa</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Serranía de Ronda</name>
      <address>
        <city>Ronda</city>
        <state>Malaga</state>
        <zip>29400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de la Axarquía</name>
      <address>
        <city>Vélez-Málaga</city>
        <state>Málaga</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios del Aljarafe</name>
      <address>
        <city>Bormujos</city>
        <state>Sevilla</state>
        <zip>41930</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Elena</name>
      <address>
        <city>Huelva</city>
        <zip>21080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</investigator_affiliation>
    <investigator_full_name>Maximo Bernabeu Wittel</investigator_full_name>
    <investigator_title>Maximo Bernabeu Wittel</investigator_title>
  </responsible_party>
  <keyword>hip fractures</keyword>
  <keyword>blood substitutes</keyword>
  <keyword>blood transfusion</keyword>
  <keyword>intravenous infusion</keyword>
  <keyword>erythropoietin, recombinant</keyword>
  <keyword>frail elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

